Trial Profile

Phase 1/2 Clinical open-label, dose-finding study of ketamine in the treatment of levodopa-induced dyskinesia in parkinsons disease

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 31 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Mar 2023 According to a PharmaTher media release, company announced an update on the Type C meeting with the US FDA for advancing KETARX towards Phase 3 clinical study as a treatment for levodopa-induced dyskinesia in Parkinson disease, the Company plans to adapt its proposed clinical development program to align with the FDA recommendations and the Company resources towards study evaluations leading into a Phase 3 study and a potential FDA marketing approval via the 505(b)(2) regulatory pathway.
11 Jan 2023 According to PharmaTher media release, the company has recently announced the presentation of the phase I/II clinical study involving ketamine in the treatment of levodopa-induced dyskinesia in Parkinson's disease.
14 Nov 2022 Results presented in a PharmaTher media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com